secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001650664-24-000120
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Q3 net loss widens to $62.1M; cash runway extended into Q2 2026
----------------------------------------------------------------------

- Q3 2024 net loss of $62.1M ($0.75/sh) vs $45.0M ($0.55/sh) in Q3 2023; R&D spend up $7.1M.
- Cash, equivalents and securities $265.1M at Sept 30; with DRI $57M upfront totals ~$322.1M.
- In vivo preclinical proof of concept for HBG1/2 editing in HSPCs using targeted LNP achieved.
- Reni-cel partnering process with Moelis & Co underway; 28-patient RUBY update at ASH in December.
- Collaboration revenue fell to $0.1M from $5.3M on prior-year Vor Bio upfront payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000120/0001650664-24-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000120/edit-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer